Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 13 images provide visual information about the product associated with Duloxetine NDC 43547-381 by Solco Healthcare Us, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

26313df6-figure-09 - 20 mg 30 capsule

26313df6-figure-09 - 20 mg 30 capsule

26313df6-figure-10 - 30mg 30 capsules

26313df6-figure-10 - 30mg 30 capsules

This text appears to be a medication label for Duloxetine Delayed-Release Capsules. It provides information on the dosage and storage instructions, including the temperature conditions for storage. The medication is manufactured by Thejan Huahai Pharmaceutical Co. in China and distributed by Soothe Healthcare in the USA. The label also includes a warning to keep the medication out of reach of children.*

26313df6-figure-11 - 60 mg 30 capsule

26313df6-figure-11 - 60 mg 30 capsule

Duloxetine Delayed-Release Capsules are medication capsules containing 67.3 mg of duloxetine hydrochloride, equivalent to 60 mg of duloxetine. Users should not use this medication if the bottle seal is missing or broken. The usual dosage is provided in the accompanying information pamphlet. The medication should be stored between 20-25°C (68-77°F) and can be briefly stored between 15-30°C (59-86°F). The medication should be stored in a tightly closed container and out of reach of children. These capsules are manufactured by The Jiangsu Hua Hai Pharmaceutical Co, Ltd., in China, and are distributed by LUPIN in Somerset, NJ 08873, USA.*

image 01

image 01

image 02

image 02

The text is a graph showing the proportion of patients with relapse over time from randomization to relapse. The graph compares two treatments, the placebo and Duloxetine. The x-axis displays time from randomization to relapse (in days), while the y-axis displays the proportion of patients with relapse. There are 6 data points displayed on the graph for each treatment over 300 days.*

image 03

image 03

image 04

image 04

image 05

image 05

image 06

image 06

The text displays a graph representing the percentage of patients improved. The horizontal axis represents the percent improvement in pain from the baseline, and the vertical axis represents the percentage of patients improved. The graph includes four different lines, each representing a different treatment: Duloxetine 120mg once daily, Duloxetine 60mg once daily, Duloxetine 20mg once daily, and Placebo.*

image 07

image 07

This is a chart indicating the percentage of patients improved with Duloxetine 60/120 mg Once daily compared to a placebo, based on the percent improvement in pain from baseline. The percentage of improvement with Duloxetine ranges from 70% to 100%, while the percentage of improvement with the placebo is not provided.*

image 08

image 08

The text shows a graph displaying the percentage of patients who showed improvement after treatment. The graph compares the effectiveness of a placebo with Duloxetine 60 mg once daily in reducing pain, with the x-axis representing the percentage of improvement in pain from baseline, and the y-axis displaying the number of patients.*

image 09

image 09

This is a graph showing the percentage of patients improved in pain from baseline (BOCF) for a placebo and Duloxetine 60/120 mg once daily. The X-axis represents percent improvement in pain and the Y-axis represents the number of patients. The graph suggests that Duloxetine may be more effective in improving pain than a placebo.*

C:\Users\RA\Desktop\duloxetine-spl\molecular.jpg - structure

C:\Users\RA\Desktop\duloxetine-spl\molecular.jpg - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.